Here is a paper analyzing the intriguing possibility that epigenetic drugs may increase the immunogenic profile of mesothelioma, thereby enhancing the ability of an immune response to target the tumor. 
HDAC inhibitors and demethylating agents open the chromatin into a conformation that facilitates transcription not only of tumor suppressors but also of tumor antigens, such as NY-ESO-1, MAGE-A1 and MAGE-A3.